Rejuvenate Bio Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Rejuvenate Bio's estimated annual revenue is currently $3.4M per year.(i)
  • Rejuvenate Bio's estimated revenue per employee is $155,000

Employee Data

  • Rejuvenate Bio has 22 Employees.(i)
  • Rejuvenate Bio grew their employee count by -66% last year.

Rejuvenate Bio's People

NameTitleEmail/Phone
1
CEO and FounderReveal Email/Phone
2
CSO and cofounderReveal Email/Phone
3
VP, Preclinical Development & Translational ScienceReveal Email/Phone
4
VP, Patient Advocacy & EngagementReveal Email/Phone
5
Chief Medical OfficerReveal Email/Phone
6
Sr. Director Regulatory and QualityReveal Email/Phone
7
Director Early R&DReveal Email/Phone
8
Research AssociateReveal Email/Phone
9
Scientific ConsultantReveal Email/Phone
10
Executive AssistantReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Rejuvenate Bio?

Rejuvenate Bio is a biotechnology company based out of United States.

keywords:N/A

N/A

Total Funding

22

Number of Employees

$3.4M

Revenue (est)

-66%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Rejuvenate Bio News

2022-04-17 - YouthBio Therapeutics: New Epigenetic Rejuvenation Startup ...

Seattle-based longevity biotech YouthBio Therapeutics has emerged from stealth mode, revealing it is working on the development of “gene...

2022-03-30 - ALS patient concerns garner FDA attention in Amylyx adcom

LONDON – In a first of its kind phase I trial, Rejuvenate Biomed NV ... Biogen, Biosion, Bio-Thera, Biovaxys, Brii, Calithera, Cellphire,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.5M2216%N/A
#2
$2.7M2216%$17.1M
#3
$1.5M22-15%$6.8M
#4
$3.9M22-4%N/A
#5
$1.8M22-24%N/A